Fulcrum Therapeutics, Inc.
FULC
$6.92
-$0.51-6.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -669.97% | -297.00% | -261.84% | 99.49% | 90.01% |
| Total Depreciation and Amortization | -12.74% | -18.48% | -24.23% | -29.64% | -26.66% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.37% | -22.20% | -19.37% | 11.48% | 15.33% |
| Change in Net Operating Assets | 192.04% | 141.13% | 68.14% | 18.67% | 7.91% |
| Cash from Operations | -2,608.07% | -596.78% | -421.41% | 108.48% | 97.56% |
| Capital Expenditure | -12.95% | -211.29% | -85.29% | 31.51% | 45.28% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4.54% | -28.97% | -68.21% | -106.71% | 189.84% |
| Cash from Investing | -4.69% | -29.58% | -68.62% | -107.00% | 187.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6,042.28% | -84.81% | -55.98% | -47.36% | -97.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6,042.28% | -84.81% | -55.98% | -47.36% | -97.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 325.30% | -159.90% | -183.48% | -58.13% | 443.56% |